Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BIRMINGHAM PAIN CENTER INC.

NPI: 1710038476 · HOOVER, AL 35244 · Psychiatry Physician · NPI assigned 01/16/2007

$71K
Total Medicaid Paid
4,630
Total Claims
4,202
Beneficiaries
6
Codes Billed
2018-01
First Month
2024-10
Last Month

Provider Details

Authorized OfficialGIBSON, LUCY (ADMINISTRATOR)
NPI Enumeration Date01/16/2007

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 968 $11K
2019 924 $11K
2020 599 $12K
2021 694 $14K
2022 631 $12K
2023 629 $8K
2024 185 $4K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 1,417 1,319 $24K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 917 871 $20K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,517 1,361 $14K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 445 365 $8K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 307 260 $5K
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) 27 26 $0.00